18F-FAMT 1985
18FLT-PET 875
25-hydroxyvitamin D 2772
3,5-diethyl-1,3,5-thiadiazinane-2-thione (DETT) 63
3DPCR 2615
3-hydroxy-3-methylglutaryl coenzyme 802
4-hydroxy tamoxifen 1488
5-aza-2′-deoxycytidine 1923
5-fluorouracil 946
5hmC 668
8q24 164
ABCB1 1673
acceleration 2217
accreditation 850
actinic keratosis 520
active surveillance 2405
activin signalling 2604
acute myeloid leukaemia 783
ADAM9 2945
ADAMs 1535
adaptive design 1950
ADCC 1221
adenocarcinoma 1571, 2688
adherence 831
adhesion 146, 753
adjuvant chemotherapy 313
adjuvant therapy 1133, 1545
adolescent 1342
advanced adenoma 1228
advanced biliary tract cancer 2165
advanced neoplasia 1334
aerobic exercise 831
AFP 2090
AFP-L3 2090
age 1125
aggressiveness 1767
Akt 399, 935, 946, 1785, 1288, 2081
Akt signalling 899
albumin 2090, 2277
alcohol 242
aldehyde dehydrogenase 3A1 2593
ALDH1 430
ALDH1A1 protein 2935
aldo-keto reductase 1C3 1506
alkylating agents 2623
allergy 1825
alpha9 1269
alpha-fetoprotein 2277
amino-acid transporter 2030
amoeboid phenotype 2099
amphiregulin 648
amplification 2914
androgen receptor gene amplification 1655
aneuploidy 2159
angiogenesis 26, 107, 115, 469, 741, 946,1027, 1034, 1179, 1269, 2700
angiogenic cytokines 441
animal welfare 928
anoikis 958
anti-angiogenesis 602, 882
anticipated delay 12
anti-inflammatory agents 1409
anti-oncomir 189
antitumour activity 1733
anti-tumour immunity 83
anxiety 868
APOBEC3 2615
apoptosis 63, 164, 341, 421, 656,753, 1645, 2144, 2224
apoptosis and cytotoxicity 146
appetite loss 1409
aromatase inhibitors 1133
ascites fluid 2269
ASCT2 2030, 2506
Asian 2187
aspirin 2378
atopy 1825
autoimmune disease 1825
autophagy 899, 2209
awareness 12
axitinib 875, 2821
B7-H3 2072
BAP1 1058
Barrett's oesophagus 775, 2378
basal cell carcinoma 1855
BCAC 535
BCAS2 2144
β-catenin 935, 2708
BCH 1985
Bcl-2 946, 1785
benchmarks 1917
benign behaviour 286
benign breast lesions 788
benzene 783
betaine 808
big five 1820
bilateral 1053
biliary cancer 882
bilirubin 2090
biliverdin 2116
biodistribution/toxicology 2441
biology 1985
biomarker strategy design 1950
biomarkers 26, 107, 123, 565, 648, 679,928, 976, 1139, 1236, 2081, 2090,2109, 2178, 2201, 2277, 2283, 2291,2462,2524, 2677, 2700, 2765, 2935
BIRC5 protein 2935
bladder cancer 679, 842, 1767, 1862,1871, 2123, 2945
blue dye 2837
BMP-6 1634
BOADICEA 535
body mass index 1133
bone marrow stroma 2099
bone metastasis 1634
borderline behaviour 286
borderline/mildly dyskaryotic cytology 1579
bortezomib 656
bowel cancer 1705
bowel cancer screening 1705
BRAF 1045, 1359
BRAF mutation 1228
brain cancer 242, 1825
brain tumour 2354
BRCA1 530, 535, 1081
BRCA1/2 1074
BRCA2 530, 535, 1081
BRD4 1189
breast cancer 4, 146, 230, 535, 560,565, 573, 715, 724, 831, 859, 916, 1081,1088, 1133, 1288, 1367, 1378,1420, 1681, 1688, 1744, 1898, 1908,1958, 2072, 2144, 2195, 2209,2327, 2412, 2524, 2623, 2765, 2772,2847, 2855, 2905
breast cancer cells 1298, 2514
breast cancer incidence 224
breast cancer metastasis suppressor gene-1 2054
breast cancer risk 224, 2339
breast cancer stem cells 2063
breast conserving surgery 1420
breast density 1908
breast screening 556
breastfeeding 1074, 1367
BRMS1 2054
bromodomain 1189
bronchitis 2796
CA-125 kinetics 1517
cachexia 1409
CAFs 724
calretinin 2040
cAMP 1278
cancer 479, 584, 1820, 1936, 2321
cancer epidemiology 7
cancer genomics 2615
cancer hallmarks 2935
cancer metabolism 330
cancer prevention 2361
cancer research 928
cancer risk 2361
cancer stem cell 430
cancer survival 1359
cancer survivors 868
cancer testes antigens 2450
cancer therapy 2496
cancer-associated fibroblast (CAF) 469
cancer-specific antigens 2450
cancer-stroma interaction (CSI) 469
capecitabine 1438
carbohydrate 1316
carbon ion radiotherapy 2389
carboplatin 256, 1923, 2975
carcinoma in situ 2604
carcinoma of unknown primary 208
cardiovascular 1338
carotene 792
case–control study 808, 1385, 2348
caspase 656
castration-resistant prostate cancer 2201, 2472
Caucasian 55
CCL7 (MCP-3) 686
CCNC 2246
CCR2 686
ccRCC 1778, 2261
CD105 1778
CD26 2232
CD43 146
CD44 916, 958, 1793
CD74 2040
CD8 2551
Cdc20 2905
CDH1 1053
CDK1 510
CDK19 2246
CDK8 2246
CDK8 submodule 2246
CDK9 1189
CDKN2A 2985
CEACAM1 1244
cell cycle 656, 2434
cell cycle-specific transgene expression 94
cell growth 2583
cell migration 706, 2569
cell-free DNA (cfDNA) 363, 2054
CellSearch system 375
cellulitis 2796
central venous access catheters 1438
cervical cancer 34, 278, 1260, 1748
cervical cytology 1841
cervical intraepithelial neoplasia 1579
cetuximab 648
cetuximab resistance 2887
c-FOS 753
chemokine 741, 1179, 1992
chemokine receptor 1992
chemoprevention 2378
chemoresistance 1785, 1958, 2881
chemosensitivity 479
chemotherapeutic sensitivity 2269
chemotherapy 49, 271, 479, 908, 1488, 1759, 2165, 2462
chemotherapy resistance 2489
child 1342
childhood 1338
childhood leukaemia 1402
Chloroquine 899
cholangiocarcinoma 882
cholecystectomy 2348
choline 808
choline kinase-alpha 330
ChREBP 715
chronic lymphoid leukaemia 783
CIMBA 535
CIN 2159
circulating endothelial cells 1236
circulating microRNAs 2462
circulating tumour cells 375
CIS 668
cisplatin 341, 625, 1163, 1733, 1785
cisplatin resistance 123
CK19 2544
classification 1688
clear cell adenocarcinoma 2881
clear cell RCC 2537
clinical 1688
clinical features 2633
clinical outcome 459
clinical trials 551
cluster randomised controlled trial 2829
c-Met 1307
c-MYC copy number gain 2688
CNS tumour 286
coculture 1552
cohort 584, 2321
cohort study 214, 249, 1316, 2339, 2354
collagen I 409
colon 459
colon cancer 435, 459, 469, 817,1211, 2081, 2310, 2544
colon neoplasms 2935
colorectal 648
colorectal adenoma 249
colorectal cancer 156, 164, 450, 530,831, 875, 935, 946, 1001, 1008, 1014,1221, 1316, 1359, 1595, 1606, 1614,1847, 2159, 2178, 2300, 2551, 2716, 2728
colorectal cancer screening 1334, 1705
colorectal neoplasms 850
communication 1101
co-morbidity 573
competing risk 1378
computed tomography 2354
concordance 1950
conditionally replicating adenoviruses 2496
consultation aid 1101
contralateral prophylactic mastectomy 1081
core biopsy 2195
Coronin 1A 1622
cost-effectiveness 1841, 2829
covariates 304
C-reactive protein 183
cross-talk 1199
CRPC 1634
cutaneous squamous cell carcinoma 520
CXCL12 1179
CXCL16 1535
CXCR4 686, 1179, 1288, 2261
CXCR6 1535
CXCR7 1179
cyclic adenosine mono-phosphate 1278
cyclooxygenase inhibitors 2378
cyclophosphamide 1733
cystectomy 1759
cysteine 71
cytidine deaminase 2615
cytochrome P450 3A (CYP3A4) 2669
cytokine receptor 133
Cytokine-induced Killer (CIK) cell 1992
cytokines 133, 733
cytostatic drug 625
DAP3 421
database 584
DCP 2090
dedifferentiation 2923
deep venous thrombosis 1118
depression 868, 1409
depressive symptoms 593
derived neutrophil–lymphocyte ratio 2531
dFdCTP 304
diabetes 1825, 1847, 2361
diagnosis 584, 1748
diagnostic algorithm 1244
diagnostic interval 584
diagnostics 976
diet 1392
dietary intake 808
dietary pattern 2785
differentiation 199
differentiation status 520
diffusion-weighted imaging (DWI) 107
diffusion-weighted MRI 616
dihydropyrimidine dehydrogenase 2728
discordance 2195
discrete choice experiment 859
disease control 1721
disease progression 2537
disease subtypes 1088
distant metastasis 1378
DJ-1 (PARK7) 1298
DLBCL 369
DNA damage response 1014
DNA demethylation 668
DNA methylation 775, 1923, 2054, 2123
DNA repair gene mutations 1663
DNMT3B 2131
docetaxel 894, 2170, 2462, 2472, 2669
Dock7 1307
dose intensification 1413
dosing schedules 1977
double and triple mutations 2812
drug resistance 1923, 2896
drug sensitivity 330
drug therapy 1943
drug–drug interaction 888
dual-imaging of virus and host cells 94
DVT 1118
dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) 107
E2 1488
early breast cancer 2187, 2450
early diagnosis 584, 1001
EBRT 2396
E-cadherin 1053
effectiveness 421, 551, 1841
efficacy 551, 1977
EGFR 648, 2116, 2688, 2716
EGFR amplification mutation 1045
EGFR and HER2 tyrosine kinase inhibitor 2647
EGFR mutation 55
EIF5A2 399, 1767
elderly 313
elective nodal irradiation 1420
embryonic stem cells 2131
Eμ-myc 928
EMT 156, 695, 724, 1958, 2000
EMT/MET 1497
EMVI 19
endometrial biopsy 609
endometrial cancer 609, 2640, 2874
endometrial cancer staging 609
endometrial carcinoma 107
endometrial carcinoma grading 609
endometrial histology 609
endometrial sampling 609
endometriosis 1878
endoplasmic reticulum stress 1488
endothelial 1778
endothelin B receptor 1027
england 1322
EpCAM 679
EPCAM protein 2935
epidemiology 242, 797, 1367, 1392, 1891
epidermal growth factor receptor 882
epigenetic silencing 636
epigenetic-gene interaction 2123
epigenetics 2874
epiregulin 648, 2716
epithelial ovarian cancer 42
epithelial–mesenchymal transition (EMT)958, 1298, 1767, 2514, 2569
ERBB2 2985
EREG 648
eribulin mesilate 1497
ERK1/2 1034, 1288
ERRβ 2144
ESMO 2640
estimates of effect 1834
ethnic 1322
ethnicity 4, 224, 230, 1433
ex vivo model 2604
expanded access 1721
expression microarray profiling 520
external quality assessment 850
external validation 42
Ezrin 695
faecal immunochemical test 1334
FAK 2747
familial prostate cancer 1663
family 1074
family history of breast cancer 2339
Fascin-1 2300
fatigue 868, 1409
FDG PET/CT 2209
female breast cancer 1891
FENSAM 2109
fetal germ cells 668
FGF receptors 1088
FGFR amplification 967
FGFR1 2914
fibrinogen 984
fibroblast growth factor receptor 320
fibrosarcoma 1456
FISH 1655
FIT 1334
flavopiridol 1189
FLT-PET 2847
fluid intake 797
fluorescence in situ hybridisation 1571, 2688, 2914
fluoropyrimidine 2728
folate 1328, 2327
FOLFIRI 875
FOLFOX 875, 1438, 2662
follow-up 19, 859, 2420
food frequency questionnaire 797
four-factor model 278
FOXO1 1260
FoxP3 1552, 2551
Foxp3+ regulatory T cells 459
free light chains 2277
FSCN1 189
FST 2144
fucosyltransferase 156
GA201 1221
Gab1 1307
galectin-1 1250
galectins 741
gallbladder cancer 882
gallstones 2348
gambogic acid 341
gastric cancer 271, 421, 967, 1169, 1199, 1211,1328, 1552, 1801, 2011, 2021, 2283, 2291, 2662, 2923
gastro-oesophageal adenocarcinoma 1525
GC 1244
G-CSF 133, 1211
G-CSFR 133, 1211
gefitinib 55
gemcitabine 83, 172, 304, 1481, 1943, 2472
gender 1385
gene expression 2662, 2728, 2738
gene expression profile 1244
gene expression profiling 1525
gene function 1552
genetic markers 2537
genetic risk 2623
genistein 1645
germ cell tumour 2738
germline mutation 1053
GIST 1155
glioblastoma 1179, 1307
glioma 242, 1825, 2560
global methylation level 2765
Glut-1 715
glyco-engineering 1221
glycosylation 2021
GNA11 1058
Golgi phosphoprotein-3 (GOLPH3) 2250
groin node 2837
growth 2300
growth factor receptors 1169
guaiac faecal occult blood test (gFOBt) 1705
guidelines 831
haeme oxygenase-1 341
haemolysis free 1001
HAGE 2450
haptokinesis 409
haptotaxis 409
HbA1c 2361
HBx 1066
HCC 1811
hCGβ 1759
head and neck cancer 501, 593, 2677
head and neck tumours 1587
health status 573
health-related quality of life 593, 2427
help-seeking 12
hepatectomy 1110
hepatocellular carcinoma 733, 1066, 1110, 2090, 2277
hepatocellular carcinoma subclasses 2708
HER2 384, 625, 2209
HER2 amplification 967
HER2-positive 2756
HER2-positive breast cancer 1139
HER3 384
HERBIS 1163
herpes zoster 2796
HGF 2716
HIF-1α 115, 1250, 1066, 2209
high risk 1074
high-grade glioma 2655
histological grade 2195
histology 1385
histomorphological marker 107
histonedeacetylase inhibitor 656, 1155
histopathological regression 1712
HLA Class I expression 459
HLA-E 459
HLA-G 459
head and neck squamous cell carcinoma (HNSCC) 2116, 2887
Hodgkin lymphoma 868
hormonal therapy 1133
hormone naïve 1655
hospitalisation 1342
HPV 1561, 1579, 1587, 1793
HPVE7 1034
HSF1 71
Hsp 90 71
human papillomavirus 489, 1587, 2369, 2804
Human teratocarcinoma stem cells 2131
humane end points 928
hyperglycaemia 2361
hypermethylation 2874
hypermutation 2615
hypertension 797
hypofractionation 2217
hypoxia 172, 715, 935, 1014, 2865
ICAM-1 1801
ID-1 1298
ifosfamide 888
IGFBP 2855
IGFBP7 775
IGFs 2865
IL15 1673
IL-6 2965
IL-8 2965
image cytometry 2159
imaging 2420
imatinib resistance 1155
immune surveillance 459
immunohistochemical subtypes 375
immunohistochemistry 775, 1525, 1571
immunosuppression 2965
immunotherapy 1472
immunotherapy vaccine 2450
impact 2804
improvement 1936
incidence 4, 535, 797, 1322
incidental breast cancer 788
infection 2796
infectious diseases epidemiology 7
inflammation 208, 435, 1930, 2524
inflammatory conditions 1825
inflammatory parameter 369
information exchange 1101
infusion rate 304
inguinofemoral lymphadenectomy 2837
inhalation 1427
inhibitors 1506
Insulin-like growth factor 2855
integrin 1269
integrin α5 764
intensity-modulated radiotherapy (IMRT) 49, 297
interaction 1359
Interlerukin-6 (IL-6) 469
interleukin-2 1427
interleukin-24 2496
interleukin-8 2047
intermediate-risk group 278
international metastatic renal cell cancer database consortium 1917
interphase-FISH 2537
interval cancer 556, 560
intervention 593
intratumoural budding (ITB) 1008
intratumoural subsites 2551
invadopodia 189
invasion 399, 1298, 1307, 2011, 2945
invasive lobular breast cancer 1053
ipilimumab 1721
iRGD peptide 1481
irinotecan 1148, 1733
irradiation 1179
JAK/STAT 133
Japan 1316
JMJD2B 1014
KDR 2700
Keap1 1785
keratinocyte 199
Ki-67 1561, 2847
Ki67 promoter 2496
kidney cancer 1622
kinase and phosphatase inhibitors 2441
KIT 1155
KLF17 1298
KLF4 450
K–PD modelling 1517
K-RAS 648, 1606, 2047 2874
KRAS gene mutation 1148
lactate dehydrogenase inhibitors 172
laparoscopic radical cystectomy 842
lapatinib 1139, 2647
laryngitis 2796
LASSO 2109
LAT1 1985, 2506
late complications 297
late effects 1338
late toxicity 49
latent class modelling (LCM) 2756
LBH589 1155
LDH5 2217
LDHA 2217
leptin 1525, 1801
leukaemia 1506, 2354
Lgr5 2011
ligands 2716
likelihood functions 34
LINE-1 repetitive sequences 2123
liposarcoma 1456
liquid chip technology 2812
liquid chromatography tandem mass spectrometry 2489
lobular carcinoma in situ 1053
local 1456
local recurrence 297
localisation 1712
locally advanced breast cancers 1413
long noncoding RNA 164
long-term survivors 2756
long-term use 249
low-dose radiation exposures 214
LRIG1 1793
lung 1936
lung adenocarcinoma (AC) 991, 2047, 2583
lung cancer 341, 764, 1385, 1834, 2427, 2688
lung carcinoid 1244
lung carcinoma 1545, 1571
lung neoplasm 908
LVSI 2640
lymph node 2544
lymph node and distant metastases 1008
lymph node excision 34
lymphatic metastasis 34
lymphocyte subsets 2551
lymphocytes 435
lymphoid malignancies 2796
lymphoma 928
lysate microarray 2072
magnetic field 1402
magnetic resonance elastography 1727
magnetic resonance imaging 1465
magnetic resonance spectroscopy 625
male 1744
male breast cancer 1891
malignant mesothelioma 510
malignant pleural mesothelioma 984, 2040, 2232
malignant progression 715
mammary gland 2747
mammary tumour 2747
mammographic density 1898, 1908
mammography 560, 2187, 2412
mammospheres 2063
MAPK pathway 520
Markov model 2412
mastectomy 2187
mathematical model 7
mathematical modelling 1517
matrix metalloproteinase 916
MDM2 656
MDSCs 83
MED13 2246
Mediator 2246
medulloblastoma 636
melanoma 399, 802, 1427, 1721, 1855, 2489, 2496
menarche 2339
Merkel cell carcinoma 1446
Merkel cell polyomavirus 1446
mesenchymal stem cells 1199
mesenchymal–epithelial transition 2514
mesothelioma 2479
meta-analysis 817, 1595, 1820, 1862,1878, 2327, 2369, 2378, 2772, 2785
metabolism 363
metastases 441
metastasis 256, 392, 450, 686, 695, 741,753, 764, 916, 1288, 1497, 1748, 2000,2011, 2072, 2099, 2144, 2300, 2310, 2537
metastasised 2738
metastatic 1125
metastatic breast cancer 375, 384, 2756
metastatic colorectal cancer 1148, 1438
metastatic prostate cancer 2462
metastatic renal cell carcinoma 1917
methylation 808
methylation-specific PCR 2054
mGPS 1930
MIB-1 2217, 2583
mice 928
microRNA 353, 991, 1199, 1614, 2072, 2945
microRNA-133b 2310
microsatellite instability 1228
microvascular density 2700
midline carcinoma 1189
MIF 2040
migration 146, 1801, 2865
minimal residual disease 2544
miR-126 2945
miR-1260b 1645
miR-145 2300
miR-196a 1260
miR-22 1250
miR-29a 450
miR-7 353
miR-9 392
MIRA 2224
miRNA 764, 1260, 2291
miRNA-9 636
mismatch repair 2728
MMP14 189
MMPs 441
MMSET 2662
model 2640
modelling 1834
molecular 1688
molecular subcategories 146
molecular subgroups 2551
monoclonal antibody 1221, 1472
morbidity 2837, 2772
mortality reduction 2412
mouse model 894, 946
MRI 625
MSC 2955
MSI 1359, 2159
mTOR inhibitor 1917
multi-arm trials 2178
multi-colour FISH 2985
multidisciplinary 1936
multimodality therapy 984
multiphase contrast-enhanced MRI 616
multiple myeloma 63
multiplex testing 2812
multivariate analysis 1712
multivitamin 249
mutant p53 2569
mutation 1066
MYC 2985
myeloma 2224
NADPH oxidase 2569
Na+/H+ exchanger 1 916
nasopharyngeal carcinoma 49, 297, 392 808, 2633
nasopharyngeal neoplasms 1465
NDC80 510
neoadjuvant 430, 1139
neoadjuvant chemoradiotherapy 19
neoadjuvant chemotherapy 421, 1413, 1420, 2847
neoadjuvant treated 1712
neoplasms 1342
neoplastic progression 2378
network meta-analysis 2396
neuroendocrine tumours 115
neuropilin-1 1481
neutropenia 271
next-generation sequencing 1663, 2738
NF-κB 63, 341, 656, 695, 2965
NICE guidelines 584
nicotine 1785
NLR 1930
nomogram 34, 1110, 1943, 2261
non-coding RNA 1614
non-malignant 286
non-melanoma 802
non-small cell lung cancer (NSCLC)55, 353, 363, 602, 991, 1236, 1930,2030, 2054, 2812, 2914
non-uptake 1705
Notch1 2283
NRF2 71
NSC23925 2896
nuclear 199
nuclear workers 214
nullipotent 2131
Nur77 935
nurse 593
NUT 1189
OATP1B 894
observational research 551
oesophageal adenocarcinoma 775, 2378, 2985
oesophageal cancer 1027, 1328, 1985
oesophageal squamous cell carcinoma 189, 2109, 2369, 2785
oesophagogastric adenocarcinomas 1712
oestradiol 1898
oestrogen receptor 1488
older 573
ombrabulin 2170
omega 6 1392, 2099
omega-3 1392
oncology 1101
oncotherapy 83
one-carbon metabolism 2123
one-carbon metabolism pathway 1328
open radical cystectomy 842
oral administration 1269
oral anticoagulant 1334
oral bioavailability 2669
oral contraceptives 1074, 1367
organic food 2321
oropharyngeal cancer 489
oropharyngeal tumours 1587
orthotopic ileal neobladder 842
orthotopic mouse model 146, 2000
OS 1811
OSNA 2544
osteopontin 1269
osteosarcoma 2896
outcomes 4, 551, 1456, 1688
outcomes assessment 1917
ovarian cancer 123, 133, 330, 625, 976, 1074,1118, 1392, 1535, 1878, 1923, 2881, 2965, 2975
ovarian cancer cells 753
ovarian epithelial cancer 1517
overall survival 42, 1433, 1917, 2021, 2261, 2283, 2700
over-diagnosis 1841, 2412
oxaliplatin 1733, 2472
p16 1561, 1587, 1793
p16ink4a 1587
p16/Ki-67 dual-stained cytology 1579
p185HER2-positive metastatic breast cancer patients 1968
p27Kip1 1260
p53 656, 2224, 2747
p95HER2 overexpression 1968
PA28gamma 353
paclitaxel 271, 1488, 1958, 2647, 2669, 2896, 2975
paediatric ALL 1673
paediatric cancer 636
pain 1409
pancreatic adenocarcinoma 1698
pancreatic cancer 183, 313, 320, 1481, 2348
pancreatic cancer cells 409
pancreatic ductal adenocarcinoma 172, 2269
pancreatic neoplasm 1943
pancreatic stellate cells 409
panobinostat 1155
parity 1074
PARP inhibitor 1977
pathogenesis of testicular cancer 2604
patient choice 573
patient preferences 859
patient survival 399
patient-reported outcomes 2427
patients' outcome 1968
pazopanib 26, 888, 2647
PC 1645
PDE4D 1278
PDE4D7 1278
PE 1118
peer 1936
peer review 850
pelvic lymph node 1748
perineural invasion 1465
peripheral blood leukocyte DNA 2765
personalised medicine 1169, 1950, 2178, 2269, 2441
personalised therapy 479
personality 1820
PET 1985
PET-CT 363
petroleum workers 783
P-glycoprotein (P-gp/MDR1) 2669
Pgp 2896
pharmacodynamics 1977
pharmacogenomics 304
pharmacokinetic study 2655
pharmacokinetics 888, 894, 1977, 2170
pharmacokinetics and pharmacodynamics 2441
pharyngitis 2796
phase I 2434
phase I/II clinical trial 2389
phosphocholine 330, 625
photodynamic therapy 1698
physical activity 1862
physical function 1409
PI3K 1045, 2081
PI3K expression 1968
PI3K7mTOR inhibitors 2887
PI3K/AKT/MDM2 2479
PI3K/AKT/mTOR 2479
piperlongumine 899
plasma 392, 1001, 2291
plasma miRNAs 976
platelet-to-lymphocyte ratio 2524
platinum 2881
Plk inhibitor 2434
PLK1 510
PLR 1930
pluripotent 2131
polypeptide N-acetylgalactosaminyl transferase-5 (GalNAc-T5) 2021
polyunsaturated fat 1392
population based 868
population pharmacokinetic model 304
population-based cohort 797
potassium intake 797
powerline 1402
PPP2CA 2000
pre-diabetes 2361
predictive 1606
predictive biomarker 320, 984, 1525
predictive factors 2195
predictive markers 1169
predictive testing 565
premenopausal 1908
preoperative AFU 1811
preoperative biopsies 1008
prevalence 2804
prevention 1681
primary care 584
primary cell cultures 2269
primary colorectal cancer 441
prior therapy 2821
progesterone receptor 565
prognosis 115, 189, 208, 230, 363, 369,489, 565, 679, 733, 775, 967, 984,1110, 1228, 1236, 1465, 1535, 1545,1552, 1561, 1595, 1614, 1673, 1744, 1759,1778, 1847, 1878, 1943, 2011, 2040, 2081,2090, 2159, 2250, 2283, 2524, 2531,2551, 2560, 2583, 2905, 2914, 2923, 2975
prognosis marker 1811
prognostic 1606, 2021
prognostic and predictive factor 2450
prognostic biomarker 1525, 2054
prognostic factors 183, 1465, 1712,2030, 2165, 2427, 2506
prognostic index 1688
prognostic marker 399, 435, 991, 2047
prognostic model 42, 2090, 2261
prognostic significance 375
prognostic value 501
prognostics 976
prognostic-score model 297
progression-free survival 1433, 1917, 2700
prokineticin 1446
proliferation 1260, 1446, 2116, 2747, 2847
prophylaxis 1427
prospective cohort 797
prospective cohort study 242
prospective study 530, 792, 2772,
prostate cancer 792, 831, 1278, 2000, 2099,2217, 2389, 2396, 2405, 2593, 2829
prostate cancer mortality 2829
prostate cancer prognosis 1655
prostate cancer stem cells 2593
prostate-specific antigen 2829
proteomic 2277
proteomics 123, 1622, 1748, 2489
PSA screening 2405
psychosocial 593
psychosomatic medicine 1820
PTEN 384, 2874
PTEN loss 1968
pulmonary 1427
pulmonary embolism 1118
pulmonary metastasis 1110
PVT-1 164
qualitative 1681, 1705
quality 1936
quality improvement 850
quality of care 551
quality of life 868
quantitative reverse transcription polymerase chain reaction (qRT–PCR) 991
Rac1 706, 1307, 2677
race 2796
RAD21 1606
radiation 214, 1472
radiation therapy 2655
radiation-induced cancer 2354
radical resection 733
radiological features 2633
radiotherapy 256, 501, 908, 1420, 2217 2389, 2623, 2633
randomised controlled study 842
rapid genetic counselling and testing 1081
Ras 1298
reactive oxygen species (ROS) 2569
rectal cancer 19, 430, 817
recurrence 19, 1456, 2935
reduction 928
reduction mammaplasty 788
refinement (3Rs) 928
registHER 2756
relapse 2420
relative risk 1663
relative survival 286
renal cancer 616, 686
renal cell cancer 797
renal cell carcinoma 1125, 1250, 2250, 2700, 2821
renal transplantation 1871
reovirus 83
replacement 928
replication competent HSV-1 94
residential distance at birth 1402
residential history 1855
resistance 479
resistance exercise 831
response biomarker 1727
RET gene rearrangement 1571
retinoblastoma 2623
retreatment 1721
retrospective analysis 1125
reverse-phase protein array 2081
reversible posterior leukoencephalopathy syndrome 602
RFS 1811
RhoA 2310
Rho/ROCK 1801
rice 1316
risk 1378, 1402, 1878
risk assessment 214
risk classification 2640
risk factor 2738
risk factors and sodium intake 797
risk prediction 535
risk stratification 2405
RNAi 510
ROS 899, 1034
ROS generation 706
ROS, reactive oxygen species 2116
RRM2 1034
RT–PCR 1488
S-1 1163
S100A13 2489
safety 1721
sarcoma 888, 1456
sarcoma
screening 1834, 2187, 2412, 2829
second-line 2165
second-line docetaxel 2662
secretome 123
securin 2905
sedentary behaviour 817
Se-methylselenocysteine 1733
seminoma 256, 2604, 2738
sentinel node 2837
SERPINB3 2708
serum 2277
sex hormone-binding globulin 1898
sFRP1 1645
short-term survivors 2756
SHP-2 2232
sialophorin 146
side-population 2063
signet ring cell cancer 1712
single-nucleotide polymorphism 1673
sirtuin inhibitor 656
sisters 1074
skin 199
skin cancer 520, 802, 1855
Skp2 1958
slice cultures 479
Smad4 946, 1645
small cell 908
small RNA 2738
small-interfering RNA 2250
smoking 242, 1359, 1385, 2339
SNP 1088
SNTA1 706
socio-economic circumstances 1705
soft tissue sarcoma 2420
solid tumours 2434
soluble CD146 1236
somatic mutations 2812
somatostatin 2232
somatostatin receptor 2 115
sorafenib 894, 1148, 1433, 2655, 2821
squamous cell carcinoma 199, 1855, 2914
squamous cell lung cancer (SCC) 991
SSTR4 2232
stage I 2187
staging 2544
standardised incidence ratio 788, 1871
STAT3 133, 1014, 1767
statin 802
stem cells 1211
stroma 441, 1744
sunitinib 616, 1125, 1433, 2441, 2700
sunlight 1058
surgery 1712
surveillance 1871
survival 115, 208, 489, 556, 908,1446, 1456, 1545, 1930, 2081, 2531, 2772
survival analysis 1378, 2935
survivin 199
survivors 1338, 1342
susceptibility 1088
symptom recognition 12
symptoms 584
synchronous colorectal cancer 1228
synovial sarcoma 1456
systematic review 2785
systemic inflammation 1409
T lymphocytes 1595
T regulatory cells 1595
tamoxifen 1681, 2874
TAp63 2310
targeted therapies 1155, 1169, 2887
targeted molecular therapy 1917
technetium 2837
teenage 1338
temozolomide 2655
temperature 928
temporal lobe injury 49
temporal lobe necrosis 2633
TERT 1058
testis 2738
testosterone 1898
testosterone levels 2201
TGF-β1, 1545, 1767
TH1 phenotype 2955
therapeutic drug monitoring 2441
therapeutic target 2677
therapy 1189
therapy resistance 2063
thromboembolism 1118
thymidylate synthase 2728
thyroid 1322
tissue culture 2604
tissue microarray 946, 2040
TMPRSS4 764
TNF 1488
TNM stage system 2109
tongue cancer 2506
tongue squamous cell carcinoma 695
tonsillectomy 2348
toxicity profile 1733
TP53 2874
TRAIL 656
trans fat 1392
transendothelial migration 2099
transforming growth factor-beta (TGF-β)156, 724, 946, 2569, 2708
transitional cell carcinoma 26, 1759
translation therapeutics 2450
trastuzumab 1139, 1163, 1472, 2209
trastuzumab-based therapies 1968
treatment 1427
treatment outcome 1721
treatment resistance 2677
Treg 1552
triple negative breast cancer 1045, 1413, 1497, 2865
tritium 214
tropomyosin-related kinase B 2923
tumour markers 1250
tumoural 1778
tumour 199, 535, 1269
tumour burden 928
tumour characteristics 1378
tumour graft 1481
tumour heterogeneity 2195
tumour infiltrating leukocyte 1446
tumour location 1595
tumour microenvironment 1199, 2955
tumour recurrence 1001, 2677, 2708
tumour size prediction 1517
tumour suppressor 353, 2144
tumour viscoelasticity 1727
tumour volume 363
tumour-associated macrophages 686
tumour-infiltrating inflammation 1595
tumour-infiltrating lymphocytes 489, 501, 2560
tumour-initiating capacity 2514
tumour-related circulating miRNA 1001
tumour–stroma ratio 1744
Twist1 958
two-stage design 1950
tyrosine kinase inhibitor 320, 1148, 2655
tyrosine kinases 2479
ubiquitination 1785
UK 4
ultrastaging 2837
ultraviolet 1855
update 535
upper tract urothelial carcinoma 2531
uptake 1681
urgent referral 584
urinary biomarkers 1622
urine 679
urothelial cancer 26
urothelial carcinoma 1759
user interface 535
uterine leiomyoma 2246
UV exposure 1058
vaccine 2804
vaginal cancer 1561
validation study 2531
vascular disrupting agent 2170
vascular endothelial growth factor receptor tyrosine kinase inhibitor 2647
vascular targeting agents 1727
vascularisation 2855
vasculogenesis 1179
vegetable 792
VEGF 469, 1433
VEGF inhibitor 1917
VEGF receptor inhibitor 2821
VEGF-A 2700
venous invasion 19
verteporfin 1698
vincristine 1189
visitatie 850
vitamin D 2772
volasertib 2434
vulval cancer 2837
warning signs 12
WNT5A 1634
women 2321
X-chromosome-linked inhibitor of apoptosis (XIAP) 2881
xCT 2506
XELOX 1438
xenograft 1977, 2855, 2975
young adult 1342
young women 1841
ziv-aflibercept 602
ZNF143 2583
ZNF217 2985
Change history
10 June 2014
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Keyword Index for Volume 110. Br J Cancer 110, 3007–3011 (2014). https://doi.org/10.1038/bjc.2014.320
Published:
Issue Date:
DOI: https://doi.org/10.1038/bjc.2014.320